Project Grant R01CA311561
Award Date 6/16/26
Completion Date 5/31/31
Dollars Obligated $409K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $431,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Albert Einstein College of Medicine, effective April 1, 2026, through March 31, 2028. This award funds research to investigate dual-targeting therapeutic approaches for acute myeloid leukemia (AML) by combining CD123-directed natural killer (NK) cell engagement with BCL-2 inhibition. The research examines the efficacy and molecular...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $772,208 Project Grant award from the National Cancer Institute (Cancer Treatment Research program, CFDA 93.395) effective April 10, 2026, with completion targeted for March 31, 2031. The research project, titled "Macrophage-Directed Strategies for BRCA-Associated Breast Cancer," develops innovative combination immunotherapy approaches to improve treatment outcomes for patients with BRCA-associated breast...
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School a $237,023 Project Grant under the Cancer Biology Research program (CFDA 93.396) on March 13, 2026, with completion scheduled for February 28, 2029. The grant funds development of high-throughput technological tools to track the fate of prematurely terminated transcripts in cancer cells, specifically focusing on alternative polyadenylation (APA) events. The research addresses a critical gap in...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $885,632 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) beginning April 2, 2026, with a completion date of March 31, 2028. This research project focuses on interrogating the erythroid differentiation and BCL-XL (B-cell lymphoma-extra large) axis in TP53-mutated acute myeloid leukemia (AML). The research aims to develop and evaluate novel therapeutic...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas Southwestern Medical Center a $688,012 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for the five-year period from June 1, 2026 through May 31, 2031. This award funds the development of novel RPS23 (ribosomal protein S23) inhibitors for the treatment of acute myeloid leukemia (AML). The research utilizes an integrated platform combining high-throughput phenotypic screening with...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $434,969 to the University of Pennsylvania through the Cancer Treatment Research program (CFDA 93.395) on May 1, 2026, for a five-year project period concluding April 30, 2031. The award supports fundamental research investigating the cellular mechanisms that sustain FLT3-mutant acute myeloid leukemia (AML) clone persistence during targeted kinase inhibitor therapy. The research combines genetically engineered...
- Federal Project Grant Award Summary Emory University received a $639,859 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective May 1, 2026 through April 30, 2031. The award supports research titled "Targeting Non-Genetic and Genetic Mechanisms to Overcome Drug Resistance in Acute Myeloid Leukemia." The research addresses the critical clinical challenge of drug resistance in acute myeloid leukemia (AML) patients, the...
- Federal Project Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a Project Grant totaling $659,201 under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026 through May 30, 2031. The research focuses on elucidating the Integrated Stress Response (ISR) pathway in glioblastoma (GBM) pathogenesis and therapeutic resistance. The project investigates how the interplay between phosphorylated eukaryotic translation initiation factor 2A...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $470,567 Project Grant (R21) award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with an ultimate completion date of June 30, 2027. The award funds research to identify molecular features that predict response or resistance to poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor therapy in metastatic breast cancer patients...